baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

HSBC TUR.WAR.OP.END. 4AB/ DE000HS35MA3 /

07/11/2024 17:37:02	Chg.-0.0200	Bid18:13:36	Ask18:13:36	Underlying	Strike price	Expiration date	Option type
0.4900EUR	-3.92%	0.4800 Bid Size: 300,000	0.4900 Ask Size: 300,000	AbbVie Inc	148.7543 USD	31/12/2078	Call

GlobeNewswire 29/08 Great Place To Work Announces the 2024 Best Workplaces in Asia Representing 6.9 Million Employee Exp...

GlobeNewswire 28/08 Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference

GlobeNewswire 28/08 Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

GlobeNewswire 23/08 NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Confere...

GlobeNewswire 19/08 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...

GlobeNewswire 15/08 Soleno Therapeutics Announces Updates to its Board of Directors

GlobeNewswire 09/08 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2...

GlobeNewswire 08/08 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08/08 Aligos Therapeutics Strengthens Board with Two New Independent Directors

GlobeNewswire 08/08 Genmab Announces Financial Results for the First Half of 2024

GlobeNewswire 08/08 Genmab Updates 2024 Financial Guidance

GlobeNewswire 08/08 Royalty Pharma Reports Second Quarter 2024 Results

GlobeNewswire 07/08 Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 01/08 Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies i...

GlobeNewswire 01/08 CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire 01/08 NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer

GlobeNewswire 01/08 Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.

GlobeNewswire 31/07 Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

GlobeNewswire 31/07 Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR...

GlobeNewswire 30/07 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...

GlobeNewswire 28/07 Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzhei...

GlobeNewswire 25/07 Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Tre...

GlobeNewswire 24/07 Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Sphe...

GlobeNewswire 24/07 Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

GlobeNewswire 24/07 OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial fo...

HSBC TUR.WAR.OP.END. 4AB/ DE000HS35MA3 /

If you wish to receive reply to your feedback, please provide your email address.